Rapt Therapeutics, Inc. (RAPT)
34.40
+0.78
(+2.32%)
USD |
NASDAQ |
Jan 12, 16:00
34.32
-0.08
(-0.23%)
After-Hours: 20:00
Rapt Therapeutics Research and Development Expense (Quarterly): 12.03M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Replimune Group, Inc. | 57.65M |
| Olema Pharmaceuticals, Inc. | 39.95M |
| NovaBay Pharmaceuticals, Inc. | -- |
| Palatin Technologies, Inc. | 2.526M |
| Theriva Biologics, Inc. | 2.551M |